NCT05653882 - A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | Biotech Hunter

Enrollment

552

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

May 31, 2027

Conditions

Solid TumorNon Small Cell Lung CancerMelanomaSquamous Cell Carcinoma of Head and NeckRenal Cell Carcinoma

Interventions

BIOLOGICAL

etakafusp alfa (AB248)

Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug

BIOLOGICAL

pembrolizumab

Intravenous infusion of pembrolizumab

Trial Locations (20)

10016

NYU, New York

10065

Memorial Sloan Kettering Cancer Center, New York

23298

Virginia Commonwealth, Richmond

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33136

University of Miami, Miami

34474

Ocala Oncology Center, Ocala

37203

Sarah Cannon Research Institute, Nashville

48201

Karmanos Cancer Institute, Detroit

60637

University of Chicago Medical Center, Chicago

63110

Washington University, St Louis

84107

Intermountain Health, Murray

90095

UCLA, Los Angeles

91010

City of Hope, Duarte

92037

UCSD, San Diego

94143

UCSF, San Francisco

97213

Providence Cancer Institute Franz Clinic, Portland

06510

Yale, New Haven

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

08901

Rutgers, New Brunswick